Skip to main content
Contact
Login
Our Company
Our Company
Mission
Leadership
Clinical Studies
Clinical Studies
ECLIPSE
GRECO-Breast Cancer
Solutions
Solutions
Treatment Selection
Residual Disease & Recurrence Monitoring
Early Detection
Biopharma Solutions
International
Investors
Investors
Media
Media
Press Releases
Resources and Media Assets
Contacts
Careers
Careers
Join Our Mission
Jobs
Press Releases
Investors Menu
Home
Press Releases
Events & Presentations
Events
Presentations
Stock Information
Stock Quote & Chart
Analyst Coverage
Financials
Quarterly Results
Annual Reports
SEC Filings
Corporate Governance
Governance Documents
Leadership
Board of Directors
Committee Composition
ESG
Resources
Investor FAQs
Investor Email Alerts
Investor Contacts
Normal
Press Release RSS Feed (opens in new window)
Press release year list
2023
2022
2021
2020
2019
2018
2017
May 31, 2023
Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting
May 26, 2023
Guardant Health to Participate in Upcoming June Investor Conferences
May 22, 2023
Guardant Health Announces Pricing of Upsized Public Offering of Common Stock
May 22, 2023
Guardant Health Announces Proposed Public Offering of Common Stock
May 17, 2023
Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling
May 16, 2023
Guardant Health Releases Inaugural ESG Report
May 9, 2023
Guardant Health Reports First Quarter 2023 Financial Results
May 9, 2023
Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test
May 8, 2023
Guardant Health Announces Additions to Leadership Team
May 5, 2023
Guardant Health Announces ECLIPSE Study Update Call on May 9, 2023
April 27, 2023
Guardant Health to Participate in the BofA Securities 2023 Healthcare Conference
April 25, 2023
Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response
April 21, 2023
Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer
April 19, 2023
Guardant Health to Report First Quarter 2023 Financial Results on May 9, 2023
April 18, 2023
Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy
April 11, 2023
Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting
March 21, 2023
Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence
March 10, 2023
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test
March 9, 2023
Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation as Detected by Guardant Health’s Guardant360 CDx Liquid Biopsy
February 27, 2023
Musa Tariq Joins Guardant Health Board of Directors
February 23, 2023
Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
February 17, 2023
Guardant Health to Participate in Upcoming March Investor Conferences
February 15, 2023
Guardant Health Initiates New Study to Examine the Impact of Shield™ Blood Test to Increase Screening Compliance for Colorectal Cancer
February 8, 2023
Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer
February 2, 2023
Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
February 2, 2023
Magistrate Judge Issues Favorable Recommendation Regarding Guardant Health’s Motion to Dismiss Lawsuit Brought by Illumina
February 1, 2023
Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
January 31, 2023
Guardant Health introduces Guardant Galaxy™ suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery
January 30, 2023
Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer
January 19, 2023
Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer
January 17, 2023
Guardant Health to showcase new data at ASCO GI 2023 demonstrating utility of its blood tests for patients with gastrointestinal cancers
January 9, 2023
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results